Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Migraine remains poorly treated, with few effective preventive drugs available. We assessed the safety and efficacy of LY2951742, a fully humanised monoclonal antibody to calcitonin gene-related peptide, for migraine prevention.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Neurol

Title: The Lancet. Neurology

ISSN (Electronic): 1474-4465

ISSN (Print): 1474-4422

Publication date (Electronic): Sep 2014

Volume: 13

Issue: 9

Affiliations

[1 ] Department of Neurology, Mayo Clinic, Phoenix, AZ, USA. Electronic address: dodick.david@mayo.edu.

[2 ] NIHR Wellcome Trust Clinical Research Facility, Kings College London, London, UK; Department of Neurology, University of California, San Francisco CA, USA.

[3 ] Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Craniofacial Pain Center, Tufts University School of Dental Medicine, Boston, MA, USA; Headache and Face Pain Program, Tufts Medical Center, Boston, MA, USA.

[4 ] Eli Lilly and Company, Indianapolis, IN, USA.

[5 ] Arteaus Therapeutics, Cambridge, MA, USA.

Article

Publisher Item ID: S1474-4422(14)70128-0

DOI: 10.1016/S1474-4422(14)70128-0

PubMed ID: 25127173

SO-VID: 8bd04c92-5fbb-4b60-901a-0bd809859619

History

Data availability:

Comments

Comment on this article

scite_

Cited by 150

See all cited by

- Version 1
- Version 1